Read the committee members' biographies and registered interests.

Dr Jane Adam (chair), MB BS, MRCP, FRCR

Jane is consultant radiologist to St. George 's Hospital, London. Her subspecialty interests include computerised tomography, magnetic resonance imaging and oncological imaging.

She is former chairman of both the Clinical Radiology Audit and Standards Subcommittees of the Royal College of Radiologists, former RCR Recertification Lead and previous member of RCR Education Board, Faculty Board and Council.

She was founding chair of the Audit and Standards Committee of the European Society of Radiology (ESR), chaired the Professional Organisation Committee, and is a former member of the ESR Executive Council.

Dr Brian Shine (vice chair)

Brian is a consultant chemical pathologist in the Oxford University Hospitals Trust and honorary senior lecturer in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford. He trained in medicine in Zimbabwe, and in clinical biochemistry at St. Bartholomew's Hospital, London, and then worked at Moorfields Eye Hospital, and Stoke Mandeville Hospital.

His clinical interests are endocrinology (particularly neuroendocrine tumours and thyroid cancer), renal stone disease, metabolic bone disease, lipid disorders, and inherited metabolic disorders. His other interests include statistics, evidence based medicine, use of information technology in laboratories, postgraduate medical education, and research ethics.

Registered interests

None.

Professor Abdallah Al-Mohammed

Abdallah is a consultant cardiologist and honorary professor of cardiology, Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield.

His special interests are in heart failure, infective endocarditis and cardiac imaging. He leads the heart failure service in Sheffield. He is an MRCP-PACES examiner.

Abdallah is a fellow of the Royal Colleges of Physicians of London and Edinburgh. He is specialty regional advisor for cardiology in South Yorkshire for both the Royal College of Physicians of London and the British Cardiovascular Society.

He is member of Council for the Royal College of Physicians of Edinburgh for Central England. He is a fellow of the European Society of Cardiology (ESC), a fellow of the Heart Failure Association (HFA) and a member of imaging group of the HFA-ESC. He is a member of the British Society for Heart Failure.

Abdallah had produced research in heart failure and cardiac imaging.

He has contributed to the work of our guidelines committees on chronic and acute heart failure, on preoperative testing and for the care of the dying adult.

Registered interests

Financial interests

Received Honorarium for:

  • Attending a meeting to discuss the heart failure services with regional team of Astra Zeneca.
  • Giving lectures in educational meeting sponsored by Janssen and Takeda.
  • Attending an advisory board on intravenous iron with Pharmacosmos.
  • Has a small private practice delivered through a limited company.

Non-financial professional and personal interests

  • Has been a principal investigator (PI) for several clinical trials in the field of heart failure between 2001 and 2020.
  • He is the PI in Sheffield for the Ironman Study.

Indirect interest

His hospital received a small grant from Astra Zeneca to purchase blood pressure machines. These were to give to patients with heart failure. This was to enable the heart failure nurses to remotely up-titrate the medication in view of the COVID-19 restrictions (£3250).

Peter Baker

Peter is a public health physician, the director of the Global Health and Development Group, Imperial College London, the deputy director of the international Decision Support Initiative, an honorary public health consultant at Imperial College Healthcare NHS Trust, and a fellow of the UK's Faculty of Public Health.

His research and public health work has focused on bringing together the health and economic professions, methods, data and analysis in order to improve the use of evidence in priority setting in health, for Tower Hamlets’ Local Authority, the NHS, Public Health England, the UK’s Department for International Development and also overseas in South Africa, Rwanda, Tanzania, Sierra Leone, Zambia and Ethiopia.

Richard M. Ballerand (lay member)

Richard is a Franco-British health policy advisor. With a dual finance and defence background, degrees in economics, strategy and psychology, a former military liaison officer, he later served as non-exec or trustee on think-tanks, boards and councils.

He chairs his GP’s patient participation group. He is a lay member on the NHSx National Data Collaborative for Health and Care, an NIHR Health Technology Assessment Prioritisation committee and the NHSE London Clinical Senate. He is an European Medicines Agency European patient expert and active health systems networker, with roles on 4 London NHS Trusts.

Richard draws on extensive lived family experience of British, French and American healthcare systems. Having sustained a traumatic brain injury during his doctoral studies, Richard has a special interest in those with invisible disabilities and in the challenges facing both ex-military and diverse communities.

Registered interests

None.

Dr Andrew Champion

Andrew is the assistant director of clinical effectiveness at the Welsh Heath Specialised Services Committee, the body responsible for commissioning specialised health services in Wales.

Andrew has worked in the NHS for almost 30 years, covering a wide range of research and managerial roles. After completing his PhD in radiation oncology in 1997, Andrew was appointed deputy programme coordinator for the National Specialist Advisory Group for Cancer. Here he managed implementation of improving outcomes guidance across Wales.

A strong interest in evidence based medicine led to Andrew's next appointment in 2003 as director of the NICE National Collaborating Centre for Cancer. In this role, he established a centre of excellence that developed over 25 separate NICE clinical guidelines. In 2016, Andrew left us to take up his current role at the Welsh Health Specialised Services Committee, where he is now embedding an evidence-based decision making approach across the organisation.

Dr Justin Daniels

Justin is a consultant paediatrician at North Middlesex University Hospital in North London. As well as being a general paediatrician, he has interests in paediatric HIV and paediatric dermatology.

Justin is a trustee of the Lullaby Trust, a charity that supports families who have lost a child due to sudden infant death syndrome.

Registered interests

None.

Dr Steven J. Edwards

Steven is the director of health technology assessment, BMJ Technology Assessment Group.

He leads one of the health technology assessment groups, funded by the National Institute for Health Research, to conduct independent research to support health policy decision making.

Since 1999, Steven has been involved in exploring methods for evidence synthesis and health economic evaluation. His primary research interests relate to making best use of the available evidence for decision making, with an emphasis on the appropriate design and conduct of studies, aggregation of clinical data, and their use in economic modelling.

Steven is an honorary lecturer in public health at the London School of Hygiene and Tropical Medicine, a member of the Cochrane Pregnancy and Childbirth Group, and the statistics advisor for diagnostic test accuracy systematic reviews for the Cochrane Skin Group. Until April 2018, Steven was a member of the our diagnostics advisory group.

Registered interests

None.

Rita Faria

Rita is a research fellow and health economist at the Centre for Health Economics, University of York. Rita has extensive experience in economic evaluation in a wide range of areas including drugs, devices, diagnostic tests and complex interventions in health and social care. Rita’s research interests are in using economic evaluation to inform complex decision problems and non-randomised data.

Registered interests

Non-personal financial interest

March 2019 to present: employer receives funding from the National Institute for Health Research to undertake a programme of technology assessment for us (assessment group, ERG and DAG work). They were awarded, led by the York Health Economics Consortium, the contract on our economic and methodological unit for public health and social care. Rita is involved in some of these projects.

Other interests

February 2017 to November 2018: presented to NICE DSU Masterclass on 'Selecting appropriate methods: the DSU algorithm' and 'Quality of effectiveness estimates from non-randomised studies'. Received a fee for presenting.

October 2016 to present: expert health economic reviewer for the Portuguese Committee for Evaluation of Health Care Technologies (Comissão de Avaliação de Tecnologias de Saúde (CATS)), for INFARMED, which is the Portuguese Health Technology Assessment Agency. In this capacity she conducts a critical appraisal of the economic evidence on drugs seeking reimbursement from the Portuguese National Health Service. The economic evidence is submitted by the manufacturer to INFARMED. She doesn't make decisions about whether the drug is cost-effective nor if reimbursement is warranted. She receives a fee for conducting each critical appraisal.

March 2018 to present: involved in the update of the methods guide for economic evaluation for the INFARMED. No payment received for this work.

Indirect interest

April 2019 to present: teaches a ABPI/NICE/DSU Masterclass each year titled 'Using non randomised data to estimate treatment effects in NICE submissions' for which she receives a fee.

Dr Michael V Holmes, MD PhD MRCP MFPM

Micheal is associate professor and pharmaceutical physician at the University of Oxford.

Michael trained in medicine, epidemiology and genetics and is undergoing specialist training in pharmaceutical physician. He is associate professor at the Nuffield Department of Population Health at the University of Oxford, where he leads genetic investigations to elucidate the causes of cardiovascular disease.

Michael is associate director of the NHS Genomic Medicine Service Alliance, which is tasked with embedding genomics into healthcare in the NHS.

Registered interests

Non-financial professional and personal interests

Unpaid consultancy for Boehringer Ingelheim, advising on pharmacogenetic investigations of medicinal products that have data from several clinical trials.

Indirect interest

Committee member of British Atherosclerosis Society.

Khalida Ismail

Khalida is a professor of psychiatry and medicine at King’s Health Partners. She has a special interest in the epidemiology of psychiatric disorders in diabetes, such as depression, eating disorders and psychotic disorders. She also has a special interest in developing and evaluating interventions to improve diabetes self-management.

Sumithra Maheswaran

Sumithra is a chief pharmacist at the London Ambulance Service NHS Trust.

Having completed her pharmacy undergraduate degree at Kings College London, Sumithra has gained extensive experience in clinical pharmacy across hospital and commissioning. She also has a Masters in Business Administration from Imperial College Business School.

Sumithra has particular interest in medication safety, evidence-based medicines and guidelines.

Registered interests

Financial interests

May 2019: Consultancy fee for advisory board 3rd April 2019 regarding a product manufactured by Veriton pharma via Integ Ltd.

G.J. Melendez-Torres DPhil RN

G.J. is a professor of clinical and social epidemiology and director of the Peninsula Technology Assessment Group at the University of Exeter, one of 9 research units in the UK providing expert advice on the clinical and cost effectiveness of new drugs to NICE. He holds first degrees in nursing and health economics as well as a doctorate in social epidemiology.

His primary interests in health technology assessment relate to applications of network meta-analysis, as well as the use of health technology assessment in public health and complex interventions.

Registered interests

Non-financial professional and personal interest

March 2019 to present: leads the Peninsula Technology Appraisal Group, commissioned to provide Health Technology Assessment for our appraisal committees.

Sarah Parry RN, BSc (Hons), MSc

Sarah is an experienced nurse and lead clinical nurse specialist for paediatric pain medicine at Bristol Royal Hospital for Children. She has clinical experience in a large variety of paediatric specialities spanning over two decades and has held a number of senior posts within the NHS. Areas of experience include research methodology, systematic reviews and patient safety with a keen focus on medication.

Sarah's qualifications include a masters in pain and advance nursing practice. She also participated in the development of the Royal College of Nursing (RCN) paediatric pain assessment guidelines. Additional roles outside of the NHS include:

  • core member of the RCN children and younger person's pain group
  • honouree lecturer at both Cardiff University and University of the West of England
  • specialist adviser for the Care Quality Commission.

Registered interests

None.

Hugo Pedder

Hugo is a statistician working within the Population Health Sciences department at the University of Bristol, where he conducts research into methods for meta-analysis and their use in technology appraisals. He is a member of the our Technical Support Unit, providing technical expertise to support the development of clinical guidelines. He previously worked as a statistician at the National Guideline Alliance, where he contributed to our guidelines on a range of topics. Whilst working in these roles, he has developed and taught on a range of courses on evidence synthesis and other statistical methods.

Hugo has an MSc in Medical Statistics from the London School of Hygiene and Tropical Medicine, and a BSc in Neuroscience from University of Edinburgh and Uppsala University. He sits on the Medical Advisory Council of the British Menopause Society as a statistical advisor. Through his involvement with the Science Media Centre and The Royal Statistical Society, he supports communication of statistics and data literacy to journalists and the wider public.

Registered interests

Financial interests

  • Consultancy statistical work for Argenx on behalf of Clifton Insight for a project on Myasthenia Gravis.
  • Named as a statistical advisor on a bid for consultancy work by PHMR in menopause. The outcome of the bid is not yet known and Hugo is not contractually committed to participating in the work.

Non-financial professional and personal interests

  • Statistical advisor to the British Menopause Society and a member of its Medical Advisory Council. This involves advising the British Menopause Society on methodological aspects of research and on communicating statistics to clinicians and patients.
  • Advocacy work for ACT-International. The charity uses a cognitive behavioural therapy for PTSD developed for use in children and adults with learning disabilities (Children’s Accelerated Traume Therapy).

Becky Pennington

Becky is a health economist at the School of Health and Related Research, University of Sheffield. Becky is a member of the Decision Support Unit and her research interests are methods for cost-effectiveness analysis. Becky is undertaking a National Institute for Health Research fellowship researching the inclusion of carer health-related quality of life in economic evaluation.

Becky has previously worked for us in developing guidelines, and in consultancy with pharmaceutical companies.

Registered interests

Non-financial professional and personal interests

January 2018 to present: involved in ongoing research project funded by National Institute for Health Research to determine cost-effectiveness of ranibizumab, aflibercept and bevacizumab for macular oedema due to central retinal vein occlusion.

January 2018 to present: authored documents submitted as evidence to technology appraisal committees relating to effectiveness and cost-effectiveness of teduglutide for short bowel syndrome.

February to November 2018: authored documents submitted as evidence to technology appraisal committees relating to effectiveness and cost-effectiveness of dinutuximab beta for neuroblastoma.

Indirect interest

May 2017 to present: employer receives payment from pharmaceutical companies for consultancy work but does not work on or receive funding from these projects.

Dominic Pivonka

Dominic is UK market access director for AbbVie Ltd, a biopharmaceutical company. He leads a team focused on enabling patient access to innovative medicines. Dominic has worked in the pharmaceutical industry for over 15 years, gaining experience across a range of therapeutic areas. He started his career in commercial roles before moving into the field of patient access and health technology assessment (HTA).

Dominic holds an MSc in Economic Evaluation for HTA from the University of York, a Postgraduate Diploma in Marketing from the Chartered Institute of Marketing, and a BSc (Hons) in Environmental Sciences from the University of East Anglia. He is also guest lecturer in the Faculty of Health and Life Sciences at Coventry University.

Pamela Rees (lay member)

After obtaining an undergraduate degree and a post graduate certificate in education, Pamela undertook postgraduate studies in urban and regional planning at the Architectural Association, London. She is currently studying for her Masters in Public Health at Nottingham University.

Pamela taught in secondary, further and adult education for over 10 years before going into youth work and then to work with Nottingham City Council in community development and regeneration. She has worked with the probation service, in both paid and voluntary roles, to address health inequalities. She is a member of the NIHR Research and Design service East Midlands Regional Advisory Board and Public Involvement committee.

In 2006-7, Pamela was a community member of the our public health programme development group for the stop smoking services guidance. She has worked with ‘disadvantaged' communities for over 30 years. For the past decade, the main focus of her work has been on improving patient and public understanding of and involvement in health; improving information and access to appropriate health care services and enabling individuals to take greater responsibility for their own health. Her commitment to social inclusion, equality and supporting public involvement in the forces that shap.

Registered interests

Other interests

June 2017 - present: a public reviewer for National Institute for Health Research and has been appointed to National Institute for Health Research East Midlands Panel for Patient Benefit. Receives an honorarium for reviewing research funding applications. None of this work has involved drugs or other technologies that have been appraised by TAC A or any other TAC that she's been a member of.

Dr Mohit Sharma

Mohit is currently a consultant in healthcare with Public Health England, where he advises the NHS from a population perspective. He is also an honorary senior clinical lecturer at the University of Oxford and has worked with the Cochrane Collaboration, and the Department of Health. He has also been a NICE Scholar.

Prior to moving into public health, Mohit worked as a surgeon for a number of years in India and in the NHS.

Registered interests

None.

Min Ven Teo

Min is a clinical pharmacist in a general practice and clinical director for the local primary care network. He was trained at the Welsh School of Pharmacy and subsequently completed an International Masters in Health Technology Assessment and Management under the Ulysses Programme. He spent 2017 to 2018 as a NICE Scholar and is currently a NICE medicine and prescribing associate.

Min has an interest in evidence based medicine and decision making.

Registered interests

Non-financial and personal interests

April 2018 to present: NICE medicines and prescribing associate.

Professor Alice Turner

Alice is a consultant in respiratory medicine, Heartlands hospital.

She graduated from the University of Leicester. She has done postgraduate training via the Universities of Dundee and Birmingham, completing a PhD focussed on COPD and alpha 1 antitrypsin deficiency (AATD).

She has been a consultant in respiratory medicine at Heartlands hospital since 2011, and is a reader in respiratory medicine at University of Birmingham. In addition she has been a member of the BTS specialist advisory group on COPD and the European Respiratory Society task force on AATD. She has published widely in COPD and AATD, and has ongoing research projects funded by the Alpha 1 Foundation, NIHR, ATS Foundation and others.

Registered interests

Financial interests

2016 to present: consultancy fee received from CSL Behring for advisory board in area of AATD; since this condition is rare it is unlikely to affect her work on committee A, as any drugs from this company would likely go to the HST committee instead. Work started 2016 and is likely to continue in financial year 2019-20.

2018: honoraria received for educational talk/event from Chiesi about COPD in 2018, not continuing in 2019-20.

2016 to present: honoraria due to be received for steering committee of an observational study run by Boehringer-Ingelheim in AATD and COPD, started 2016 and study recently extended to 2021.

Indirect interest

2017 to present: employer manages research grant from AstraZeneca for a study in COPD due to end 2020.

2018 to present: employer manages research grant from Chiesi for a study in COPD due to end 2021.

April 2019 to present: employer manages research grant from CSL Behring for a study in AATD. Currently going through contracting, due to end in 2020.

Dr Roger Whittaker

Roger is a clinical senior lecturer, Institute of Neuroscience, Newcastle University.

He is also professor of clinical neurophysiology in the Translational and Clinical Research Institute, Newcastle University, and Honorary Consultant in the Department of Clinical Neurophysiology in the Royal Victoria Infirmary, Newcastle upon Tyne. His clinical and research focus is on developing and testing novel diagnostic techniques for patients with neurological diseases.

Registered interests

None.

Back to top

More information

Find out more about the committee and read papers from previous meetings.

About the technology appraisal committee

Get involved

Find out when TAC meetings are held and how to register to attend.